AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Summary
•
Newmont’s intraday rally reflects a confluence of strategic asset management and broader macroeconomic tailwinds. The stock’s 3.88% surge, driven by the Fuerte Metals divestiture and a gold market boom, underscores investor confidence in the company’s capital allocation strategy. With gold prices surging past $4,400 and the Federal Reserve signaling rate cuts, NEM’s technicals and fundamentals align for a bullish continuation.
Strategic Divestiture and Gold Market Momentum Drive NEM's Surge
Newmont’s 3.88% intraday gain is fueled by two key catalysts: the $29.5 million secondary offering of Fuerte Metals shares and a record-breaking gold rally. The divestiture reduces NEM’s stake in Fuerte from 24% to 19.5%, signaling a strategic pivot toward core assets. Meanwhile, gold prices have surged 68% year-to-date, driven by geopolitical tensions, U.S. fiscal deficits, and expectations of further Fed rate cuts. NEM’s Zacks Rank 3 (Hold) contrasts with Kinross Gold’s 1 (Strong Buy), but its 169.9% annual gain outpaces the industry’s 151.8% rise, reflecting strong operational execution and capital discipline.
Gold Sector Rally Gains Momentum as Kinross Gold Surges 2.89%
The gold sector is in a synchronized upswing, with Newmont’s 3.88% gain outpacing Kinross Gold’s 2.89% rally. Both stocks benefit from gold’s record highs, but NEM’s strategic divestiture and robust free cash flow ($1.6 billion in Q3) provide a structural edge. Zacks Consensus estimates highlight KGC’s 147.1% EPS growth for 2025, but NEM’s 74.1% projection, combined with a 14.89 P/E, suggests undervaluation relative to its peers. The sector’s technical strength is reinforced by central bank gold purchases and a weakening dollar.
Options Playbook: and Lead the Charge
• 200-day SMA: $68.12 (well above)
• RSI: 70.25 (overbought)
• MACD: 3.60 (bullish divergence)
• Bollinger Bands: Price at $105.22 vs. upper band $103.71 (oversold)
NEM’s technicals suggest a continuation of its bullish trend, with key resistance at $105.59 (52-week high) and support at $93.14 (20-day SMA). The options chain reveals two high-conviction plays: NEM20251226C105 and NEM20251226C106.
• NEM20251226C105
- Strike: $105 | IV: 34.19% | Leverage: 55.46% | Delta: 0.548 | Theta: -0.5166 | Gamma: 0.0939 | Turnover: 473,796
- Payoff: At 5% upside ($110.48), payoff = $5.48 per share. High leverage and moderate delta make this ideal for a 5–7% move.
• NEM20251226C106
- Strike: $106 | IV: 33.88% | Leverage: 75.27% | Delta: 0.3286 | Theta: -0.3358 | Gamma: 0.1064 | Turnover: 15,400
- Payoff: At $110.48, payoff = $4.48 per share. High gamma and leverage suit aggressive bulls expecting a breakout.
Aggressive bulls should consider NEM20251226C105 into a test of $105.59 resistance. A close above this level could trigger a retest of the $108–$110 range.
Backtest Newmont Stock Performance
The backtest of NEM's performance following a 4% intraday surge from 2022 to the present indicates positive short-to-medium-term gains. The 3-day win rate is 53.24%, the 10-day win rate is 57.49%, and the 30-day win rate is 61.74%, suggesting that
Bullish Momentum Unlikely to Subside—Position for NEM's Next Move
Newmont’s rally is underpinned by strategic clarity, gold’s macro tailwinds, and robust technicals. The stock’s 3.88% gain today, coupled with a 54.7% premium above its 200-day SMA, signals a high-probability continuation. Investors should monitor the $93.14 support level and watch for a breakdown below $90 to confirm a reversal. Meanwhile, the sector leader Kinross Gold (KGC) surges 2.89%, but NEM’s valuation and execution edge make it the superior play. Act now: Buy NEM20251226C105 for a 5–7% target or short-term cash-secured puts if $93.14 breaks.
TickerSnipe provides professional intraday stock analysis using technical tools to help you understand market trends and seize short-term trading opportunities.

Dec.22 2025

Dec.22 2025

Dec.22 2025

Dec.22 2025

Dec.22 2025
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet